News

Sakura Finetek Japan Co., Ltd. (Head Office: Chuo-ku, Tokyo; President and CEO: Satoru Ishizuka), a total supplier of pathology instruments and equipment, announced that it has established new local subsidiary in Malaysia, called Sakura Finetek Malaysia Sdn. Bhd. located at Subang Jaya, Selangor, Malaysia, and will commence operations in October this year.
The new base will strengthen customer support in the fast-growing South East Asian market and further accelerate our overseas expansion.

Southeast Asia is a market that is expected to expand in line with economic growth and longer life expectancy. Since the opening of our Asia Regional Office in Malaysia in 2019, we have strengthened our customer support and sales activities in the South East Asian market. With the establishment of this new legal entity, we aim to further strengthen these efforts and increase awareness of the Sakura Finetek Group and our products.

The Sakura Finetek Group (Sakura Finetek USA, Sakura Finetek Europe and Sakura Finetek Japan) works globally to realize its mission of “Advancing cancer diagnostics by providing integrated solutions for anatomic pathology and patients through best-in-class innovation, quality and customer care”.

As a total solution provider in pathology, Sakura Finetek Japan will provide optimal products, reagents and services to help improve the efficiency and accuracy of pathology specimen preparation.

■ Outline of new subsidiary in Malaysia

Name ： Sakura Finetek Malaysia Sdn. Bhd.
Registration No. 202401026161 (1572010-W)

Location ： Subang Jaya, Selangor
Address：E-02-01A, Sunway Geo Avenue, Jalan Lagoon Selatan, Bandar Sunway, 47500 Subang Jaya, Selangor Darul Ehsan, Malaysia

Date of Establishment ： 29 August, 2024

Representative ： Managing Director: Yoshihiro Horiuchi

Business activities ： Sales and customer support of specimen preparation equipment, instruments, reagents and other related products for the pathology field in the Southeast Asian region.

■Sakura Finetek Group Mission
We are committed to advancing cancer diagnostics by providing integrated solutions (product, application and service) for pathology and patients through best-in-class innovation, quality and customer care.